American Century Companies Inc. Acquires 27,619 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

American Century Companies Inc. lifted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 356,576 shares of the biopharmaceutical company's stock after acquiring an additional 27,619 shares during the period. American Century Companies Inc. owned 0.30% of Cytokinetics worth $16,773,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC lifted its position in Cytokinetics by 4.0% in the third quarter. Geode Capital Management LLC now owns 2,848,584 shares of the biopharmaceutical company's stock worth $150,433,000 after purchasing an additional 109,938 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Cytokinetics by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,335,189 shares of the biopharmaceutical company's stock worth $62,807,000 after buying an additional 13,798 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Cytokinetics by 17.2% during the third quarter. Janus Henderson Group PLC now owns 1,143,830 shares of the biopharmaceutical company's stock valued at $60,399,000 after buying an additional 167,501 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Cytokinetics by 13.7% during the fourth quarter. Fisher Asset Management LLC now owns 616,492 shares of the biopharmaceutical company's stock valued at $29,000,000 after buying an additional 74,208 shares in the last quarter. Finally, Checkpoint Capital L.P. grew its holdings in Cytokinetics by 145.7% during the third quarter. Checkpoint Capital L.P. now owns 466,813 shares of the biopharmaceutical company's stock worth $24,648,000 after acquiring an additional 276,813 shares during the period.

Remove Ads

Insider Activity

In other Cytokinetics news, EVP Andrew Callos sold 3,341 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now owns 64,434 shares of the company's stock, valued at $2,788,059.18. This represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert I. Blum sold 15,000 shares of Cytokinetics stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $40.75, for a total transaction of $611,250.00. Following the completion of the transaction, the chief executive officer now directly owns 427,629 shares in the company, valued at approximately $17,425,881.75. This represents a 3.39 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,284 shares of company stock worth $2,578,268. 3.40% of the stock is owned by corporate insiders.

Cytokinetics Stock Down 7.8 %

Cytokinetics stock traded down $3.16 during trading hours on Friday, hitting $37.36. The company had a trading volume of 3,208,825 shares, compared to its average volume of 1,545,467. The firm's fifty day moving average is $44.93 and its 200-day moving average is $48.98. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a fifty-two week low of $36.89 and a fifty-two week high of $75.71. The firm has a market capitalization of $4.42 billion, a P/E ratio of -6.94 and a beta of 0.94.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million. On average, research analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CYTK. Citigroup began coverage on shares of Cytokinetics in a research report on Friday, February 7th. They set a "buy" rating and a $86.00 price objective for the company. Stifel Nicolaus started coverage on shares of Cytokinetics in a report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 target price for the company. JMP Securities reiterated a "market outperform" rating and set a $78.00 price objective on shares of Cytokinetics in a research report on Friday, February 7th. Morgan Stanley set a $67.00 price objective on Cytokinetics in a research note on Friday, March 7th. Finally, Royal Bank of Canada boosted their target price on Cytokinetics from $80.00 to $82.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $82.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.